JY
BIOTU

Jeff Yass’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Jeff Yass’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60,459
Closed -$598K – 13523
2021
Q1 		$598K Buy
+60,459
New +$622K ﹤0.01% 9071

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's BIOTU Position: Q2 2021 in Review

Jeff Yass sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2021, closing a stake of 60,459 shares — an estimated $598K sold.

Jeff Yass first reported a position in BIOTU in Q1 2021 and held it in 1 quarter. The position peaked at $598K in Q1 2021. 41 funds tracked by Wall St. Rank hold BIOTU as of Q2 2021.

  • Jeff Yass reported no remaining Biotech Acquisition Company Unit position as of Q2 2021 after selling out during the quarter.
  • Jeff Yass sold 60,459 Biotech Acquisition Company Unit shares in Q2 2021, an estimated $598K.
  • Jeff Yass first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 1 quarter.
  • Jeff Yass's Biotech Acquisition Company Unit position peaked at $598K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2021.

Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.